Justin Hirsch
@Octagon Capital Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$642.902MTotal holdings41
Assets growth rate1.05%Assets growth rate (2-Q avg)-11.35%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Octagon Capital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.
Assets under management
The assets under management (AUM) of Octagon Capital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 642.902M in assets, with a quarterly growth rate of 1.05% and a 2-quarter average growth rate of -11.35%. The portfolio is managed by Justin Hirsch, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
TERNTerns Pharmaceuticals Inc
| 0% | $9.292M 1.364M shares@ $6.81 avg price | Exited |
ANTXAn2 Therapeutics Inc
| 0% | $6.924M 3.22M shares@ $2.15 avg price | Exited |
AKROAkero Therapeutics Inc
| 0% | $6.648M 283,372 shares@ $23.46 avg price | Exited |
JSPRJasper Therapeutics Inc
| 0% | $6.526M 287,500 shares@ $22.7 avg price | Exited |
CYBNCybin Inc
| 0% | $5.042M 18.605M shares@ $0.28 avg price | Exited |
SLNSilence Therapeutics Plc
| 0% | $3.344M 176,000 shares@ $19.0 avg price | Exited |
PSTXPoseida Therapeutics Inc
| 0% | $2.149M 736,000 shares@ $2.92 avg price | Exited |
ELEVElevation Oncology Inc
| 0% | $2.017M 747,000 shares@ $2.7 avg price | Exited |
FATEFate Therapeutics Inc
| 0% | $1.708M 520,800 shares@ $3.28 avg price | Exited |
ACETAdicet Bio Inc
| 0% | $929,037 767,799 shares@ $1.22 avg price | Exited |